MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma

The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported. Accordingly, we established sorafenib-resistant HCC cells and investigated the underlying mechanism of resistance to sorafenib. Sorafeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomonari, Tetsu, Takeishi, Shunsaku, Taniguchi, Tatsuya, Tanaka, Takahiro, Tanaka, Hironori, Fujimoto, Shota, Kimura, Tetsuo, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872779/
https://www.ncbi.nlm.nih.gov/pubmed/26769852
http://dx.doi.org/10.18632/oncotarget.6889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872779/
https://www.ncbi.nlm.nih.gov/pubmed/26769852
http://dx.doi.org/10.18632/oncotarget.6889

Ejemplares similares